Halozyme Therapeutics (HALO) Tops Q4 EPS by 13c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Halozyme Therapeutics (HALO) PT Raised to $19 at BMO Capital
February 21, 2018 8:42 AM ESTBMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $18.00) while maintaining a Market Perform rating.
Analyst Do Kim said they believe ENHANZE continues to provide a strong valuation floor with Janssen conducting six studies. However, PEGPH20 Phase III interim data in 4Q18 remains a key risk.
... MoreHalozyme Therapeutics (HALO) PT Raised to $22 at JPMorgan
February 21, 2018 7:24 AM ESTJPMorgan raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $22.00 (from $19.00) while maintaining a Overweight rating.
... MoreHalozyme Therapeutics (HALO) PT Raised to $24 at Deutsche Bank
February 21, 2018 6:55 AM ESTDeutsche Bank raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $24.00 (from $21.00) while maintaining a Buy rating following the company's 4Q earnings report. Results were in line with our expectations given the preliminary announcement of results earlier this year. +24.6% y/y royalty... More
